Molecular Partners Ag (MOLN) Income from Continuing Operations (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Income from Continuing Operations of 16792.1 for Q1 2026, up 10.0% year-on-year from 15266.22 in Q1 2025, and up 99.98% on a QoQ basis from 81842757.58 in Q4 2025.
Molecular Partners Ag (MOLN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Income from Continuing Operations for 7 consecutive years, with 16792.1 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 10.0% year-over-year to 16792.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81898998.29 (down 31.54% YoY) and the FY2025 annual result came in at 81904076.91, down 31.55% from the prior year.
- Income from Continuing Operations advanced to 16792.1 in Q1 2026 per MOLN's latest filing, from 81842757.58 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MOLN reached as high as 127712738.23 in Q4 2022 and fell as low as 81842757.58 in Q4 2025.
- A 5-year average of 6522976.35 and a median of 16792.1 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 1005.54% — and 2023, when it tumbled 278.7%.
- Year by year, Income from Continuing Operations stood at 127712738.23 in 2022, then plunged by 156.44% to 72074910.74 in 2023, then grew by 13.69% to 62209725.39 in 2024, then sank by 31.56% to 81842757.58 in 2025, then surged by 99.98% to 16792.1 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 16792.1, 81842757.58, and 14803.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -16,792.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,792.10 |
| Dec 31, 2025 | -81.84 Mn |
| Sep 30, 2025 | -14,803.30 |
| Jun 30, 2025 | -24,645.31 |
| Mar 31, 2025 | -18,656.89 |
| Dec 31, 2024 | -62.21 Mn |
| Sep 30, 2024 | -18,940.19 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,981.38 |
| Dec 31, 2023 | -72.07 Mn |
| Sep 30, 2023 | -12,957.15 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,983.58 |
| Dec 31, 2022 | 127.71 Mn |
| Sep 30, 2022 | -13,800.36 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 165,800.92 |
| Dec 31, 2021 | -69.13 Mn |
| Sep 30, 2021 | -13,411.64 |
| Jun 30, 2021 | -36.79 Mn |